← Catalyst calendarATOS biotech catalysts & pipeline
ATOSSA THERAPEUTICS INC · Data as of 2026-09-08
Upcoming catalysts
(Z)-endoxifen — Topline data
Q3 2026
The follow up 24-month mammographic record review of participants was concluded as of March 31, 2026, and top-line durability data is expected to be received before the end of the third quarter of 2026.
Source filing(Z)-endoxifen — Initial data
H2 2026
Enrollment for all arms of this expanded study using (Z)-endoxifen as a combination therapy is complete, and we expect to begin receiving data throughout the second half of 2026.
Source filingExplore the free biotech catalyst calendar